The dynamics and interaction of endothelium state and immune status variations in program hemodialysis patients against the background of atorvastatin therapy

Sovremennye Tehnologii v Medicine

Volumn 5, Issue 2, 2013, Pages 78-82

  Barsuk, A L ^a   Vozova, A M ^a   Malinok, Y E ^a   Lovtsova, L V ^a   Okrut, I E ^a   Kuzin, V B ^a  

^a PRIVOLZHSKY RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Atorvastatin; Endothelium state in PHD; Immune status in PHD; Program hemodialysis (PHD)

Indexed keywords

ATORIS; ATORVASTATIN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; ENDOTHELIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HELPER CELL; HEMODIALYSIS; HUMAN; IMMUNE STATUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; SPECTROPHOTOMETRY; T LYMPHOCYTE;

EID: 84879151538     PISSN: 20764243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rtisheva O.V., Kalev O.A., Akhmatov V.Yu. Struktura prichin letal'nykh iskhodov u bol'nykh, nakhodyashchikhsya na programmnom gemodialize. Klinicheskaya nefrologiya [The structure of causes of lethal outcomes in program hemodialysis patients]. Klinicheskaya nefrologiya - Clinical Nephrology 2011; 1: 43-45.
2. Susekov A.V. Giperlipidemiya - sovremennoe sostoyanie problemy i metody ee medikamentoznoy korrektsii [Hyperlipidemia - present problem state and the methods of its medical correction]. Rus Med Z - Russian Medical Journal 2003; 5: 267-270.
3. Fesenko E.V., Proshchaev K.I., Polyakov V.I. Pleyotropnye effekty statinov i ikh rol'v preodolenii problemy polimorbidnosti [Pleiotropic action of statins and their role in overcoming the problem of multimorbidity]. Covremennye problemy nauki i obrazovaniya - Present problems of Science and Education 2012; 2: 1-8.
4. Parkhomenko A.N., Lutay Ya.M. Rannee primenenie simvastatina u bol'nykh s ostrym koronarnym sindromom: vliyanie na dinamiku markerov vospaleniya i rezul'taty klinicheskikh nablyudeniy [Early simvastatin administration in patients with acute coronary syndrome: the effect on inflammation markers dynamics and the results of clinical observations]. Ukrainskiy kardiologichniy zhurnal - Ukrainian Cardiological Journal 2005; 3: 36-45.
5. Han S.H., Kang E.W., Yoon S.J., et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2011; 26(11): 3722-3728.
6. Kishimoto N., Hayashi T., Sakuma I., et al. A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis. Int J Cardiol 2010; 145(1): 21-26.
7. Karpov Yu.A., Sorokin E.V. Ateroskleroz i faktory vospaleniya: nelipidnye mekhanizmy deystviya statinov [Atherosclerosis and inflammatory factors: non-lipid mechanisms of statins]. Rus Med Z - Russian Medical Journal 2001; 10: 418-421.
8. Pertosa G., Grandaliano G., Simone S. et al. Inflammation and carnitine in hemodialysis patients. J Ren Nutr 2005; 15(1): 8-12.
9. Goicoechea M., Quiroga B., Garcia de Vinuesa S., et al. Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease. Ren Fail 2012; 34(8): 1002-1009.
10. Kessler M., Kano B., Pedrini L.A., et al. Evropeyskie rekomendatsii po optimalnoy praktike gemodializa. Chast'1 [European recommendations for optimal hemodialysis. Part 1]. Oxford (UK): Oxford University Press; 2005; 112 p.
11. Jourde-Chiche N., Dou L, Cerini C, et al. Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011; 24(3): 327-337.
12. Malyszko J., Malyszko J.S., Hryszko T., et al. Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis. Int J Tissue React 2002; 24(3): 111-115.
13. Korybalska K., Kawka E., Breborowicz A., Witowski J. Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury. J Physiol Pharmacol 2012; 63(4): 389-395.
14. + regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther 2008; 6(7): 987-997.
15. Atamanova T.Yu. Vliyanie dlitel'noy terapii statinami na immunnuyu sistemu bol'nykh ishemicheskoy bolezn'yu serdtsa. Avtoref. Dis. kand. med. nauk [The effect of a long-term statin therapy on immune system of ischemic patients: Abstract for Dissertation for the degree of Candidate of Medical Science]. Chelyabinsk; 2006.